About TenNor Therapeutics
TenNor Therapeutics is a company based in Suzhou (China) founded in 2013.. TenNor Therapeutics has raised $108.62 million across 5 funding rounds from investors including AMR Action Fund, Zhongshan Investment Holding Group and Yanchuang Capital. TenNor Therapeutics operates in a competitive market with competitors including Paratek Pharma, Spero Therapeutics, Cempra, Bugworks Research and Locus Biosciences, among others.
- Headquarter Suzhou, China
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$108.62 M (USD)
in 5 rounds
-
Latest Funding Round
$42.16 M (USD), Series E
Oct 16, 2024
-
Investors
AMR Action Fund
& 10 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Unlock access to complete
Leadership Team
6 people
Advisor Team
4 people
Product Management Team
1 people
Unlock access to complete
Funding Insights of TenNor Therapeutics
TenNor Therapeutics has successfully raised a total of $108.62M across 5 strategic funding rounds. The most recent funding activity was a Series E round of $42.16 million completed in October 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 5
- Last Round Series E — $42.2M
- First Round First Round
- Investors Count 11
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct, 2024 | Amount | Series E - TenNor Therapeutics | Valuation | AMR Action Fund , unknown |
|
| Mar, 2022 | Amount | Series D - TenNor Therapeutics | Valuation |
investors |
|
| Oct, 2020 | Amount | Series B - TenNor Therapeutics | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in TenNor Therapeutics
TenNor Therapeutics has secured backing from 11 investors, including venture fund and institutional investors. Prominent investors backing the company include AMR Action Fund, Zhongshan Investment Holding Group and Yanchuang Capital. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investments are made in antimicrobial resistance treatment development.
|
Founded Year | Domain | Location | |
|
-
|
Founded Year | Domain | Location | |
|
-
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by TenNor Therapeutics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - TenNor Therapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Tennor Therapeutics Comparisons
Competitors of TenNor Therapeutics
TenNor Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Paratek Pharma, Spero Therapeutics, Cempra, Bugworks Research and Locus Biosciences, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Therapeutics for antimicrobial resistant infections are developed.
|
|
| domain | founded_year | HQ Location |
Therapeutics for drug-resistant bacterial infections are developed.
|
|
| domain | founded_year | HQ Location |
Clinical-stage pharmaceutical company focused on developing antibacterials
|
|
| domain | founded_year | HQ Location |
Drugs for antibiotic-resistant infections and cancer are developed.
|
|
| domain | founded_year | HQ Location |
Developer of therapeutics for infectious disease and inflammatory indications
|
|
| domain | founded_year | HQ Location |
Therapies for multi-drug resistant infections are developed using bacteriophages.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Tennor Therapeutics
Frequently Asked Questions about TenNor Therapeutics
When was TenNor Therapeutics founded?
TenNor Therapeutics was founded in 2013 and raised its 1st funding round 3 years after it was founded.
Where is TenNor Therapeutics located?
TenNor Therapeutics is headquartered in Suzhou, China. It is registered at Suzhou, Jiangsu, China.
Is TenNor Therapeutics a funded company?
TenNor Therapeutics is a funded company, having raised a total of $108.62M across 5 funding rounds to date.
What does TenNor Therapeutics do?
TenNor Therapeutics was founded in 2013 in Suzhou, China, focusing on the biotechnology sector. Small molecule therapeutics targeting GI tract infections are developed, with the lead candidate TNP-2092a rifamycin-based bifunctional moleculehaving completed Phase 1 clinical trials via intravenous dosing. Additional candidates, including TNP-2198 and TNP-2500, are under development. Expansion into areas such as C. difficile infection, hepatic encephalopathy, and Crohns disease is planned.
Who are the top competitors of TenNor Therapeutics?
TenNor Therapeutics's top competitors include Spero Therapeutics, Melinta Therapeutics and Vedanta Biosciences.
Who are TenNor Therapeutics's investors?
TenNor Therapeutics has 11 investors. Key investors include AMR Action Fund, Zhongshan Investment Holding Group, Yanchuang Capital, ShenZhen GTJA Investment Group, and unknown.